Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 17;2(3):167-175.
doi: 10.1002/ags3.12071. eCollection 2018 May.

Recent advances in treatment for colorectal liver metastasis

Eiji Oki  1 , Koji Ando  1 , Ryota Nakanishi  1 , Masahiko Sugiyama  1 , Yuichiro Nakashima  1 , Nobuhide Kubo  1 , Kensuke Kudou  1 , Hiroshi Saeki  1 , Tadahiro Nozoe  1 , Yasunori Emi  1 , Yoshihiko Maehara  1
Affiliations
Review

Recent advances in treatment for colorectal liver metastasis

Eiji Oki et al. Ann Gastroenterol Surg. .

Abstract

A major challenge for the management of colorectal liver metastasis (CRLM) is the multidisciplinary approach including surgery. Resection is the most important treatment strategy to prolong the survival of patients with colorectal cancer (CRC). Even when resection is not possible as a primary treatment, it may still be carried out for curative intent after effective chemotherapy. Therefore, resection should always be considered when conducting chemotherapy for CRLM. Neoadjuvant anti-epidermal growth factor receptor (EGFR) antibody has shown a high response rate for RAS wild CRC. However, whether anti-EGFR antibody is superior to antivascular endothelial growth factor antibody for all types of CRLM is yet to be determined. Recently, several randomized control trials of first-line therapy for advanced CRC have been conducted, and some of them are ongoing. The optimal chemotherapy regimen and tumor biology indicated for neoadjuvant chemotherapy as well as conversion surgery are expected to be determined in the near future.

Keywords: RAS; chemotherapy; colorectal cancer; conversion therapy; liver metastasis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment flow for colorectal cancer liver metastasis. EGFR, epidermal growth factor receptor; 5‐FU/LV, fluorouracil/leucovorin
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. - PubMed
    1. Cancer Statistics in JAPAN‐2016 . In: Foundation for Promotion of Cancer Research; 2018. Available from https://ganjoho.jp/reg_stat/statistics/brochure/backnumber/2016_jp.html
    1. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long‐term survival. Ann Surg. 2004;240:644–57; discussion 657‐8. - PMC - PubMed
    1. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311–9. - PubMed
    1. Watanabe T, Muro K, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1–34. - PMC - PubMed